Table 1.
Description of the patient selection
| Patient | Breed | Age (years) |
Sex | Body weight (kg) | Tumour type | CYC schedule | CYC dose (mg/m2) |
Primary tumour |
Metastasis | Additional drugs |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DSH | 11 | FN | 4.30 | Injection site sarcoma | q24h | 10.0 | Microscopic | No | None |
| 2 | DSH | 10 | FN | 3.44 | Hemangiosarcoma (subcutaneous) | Twice weekly | 21.0 | Microscopic | No | Meloxicam |
| 3 | DLH | 7 | MN | 4.75 | Injection site sarcoma | EOD | 17.0 | Macroscopic | LN | Toceranib + meloxicam |
| 4 | DSH | 9 | MN | 6.50 | Injection site sarcoma | EOD | 14.0 | Microscopic | No | Meloxicam |
| 5 | DSH | 8 | MN | 4.20 | Angioleiomyosarcoma | EOD | 19.0 | Microscopic | No | Toceranib + meloxicam |
| 6 | DSH | 9 | FN | 4.60 | Injection site sarcoma | EOD | 16.0 | Microscopic | No | Toceranib + meloxicam |
| 7 | DSH | 18 | MN | 5.80 | Injection site sarcoma | q24h | 15.0 | Microscopic | No | Meloxicam |
| 8 | Egyptian | 12 | FN | 3.70 | Injection site sarcoma | EOD | 10.0 | Macroscopic | No | Thalidomide |
| 9 | DSH | 14 | FN | 2.75 | Oral fibrosarcoma | q24h | 10.0 | Macroscopic | No | Meloxicam |
| 10 | Siamese | 8 | MN | 5.00 | Oral fibrosarcoma | EOD | 8.5 | Macroscopic | No | Piroxicam |
| 11 | Maine Coon | 7 | MN | 8.70 | Hemangiosarcoma (subcutaneous) | EOD | 6.0 | Macroscopic | No | Thalidomide + piroxicam |
| 12 | Maine Coon | 13 | MN | 6.20 | Injection site sarcoma + hepatocellular carcinoma | q24h | 15.0 | Macroscopic | No | None |
| 13 | DSH | 14 | FN | 4.50 | Injection site sarcoma + cholangiocarcinoma + thyroid carcinoma | EOD | 9.0 | Macroscopic | Liver | Thalidomide + piroxicam |
| 14 | DSH | 8 | FN | 4.10 | Nasal squamous cell carcinoma | q24h | 15.0 | Macroscopic | No | Meloxicam |
| 15 | DSH | 16 | FN | 4.50 | Nasal carcinoma | q24h | 10.0 | Microscopic | No | Firocoxib |
| 16 | DSH | 10 | FN | 3.60 | Nasal squamous cell carcinoma | q24h | 15.0 | Macroscopic | No | Meloxicam |
| 17 | DSH | 19 | MN | 4.10 | Unknown origin carcinoma | EOD | 10.0 | Not assessable | Lungs | None |
| 18 | DSH | 12 | FN | 2.90 | Hepatocellular carcinoma | EOD | 12.5 | Macroscopic | Regional LN pancreas | Thalidomide + piroxicam |
| 19 | DSH | 15 | FN | 2.90 | Oral squamous cell carcinoma | q24h | 15.0 | Macroscopic | No | None |
| 20 | Persian | 14 | MN | 3.00 | Renal carcinoma | EOD | 12.0 | Macroscopic | LN | Thalidomide + piroxicam |
| 21 | DSH | 12 | FN | 4.50 | Mammary carcinoma | q24h | 15.0 | Macroscopic | No | Meloxicam |
| 22 | DSH | 16 | FN | 2.43 | Pancreatic adenocarcinoma | EOD | 27.0 | Macroscopic | LN and lungs | Toceranib |
| 23 | DSH | 11 | MN | 5.50 | Neuroendocrine tumour | EOD | 8.0 | Macroscopic | Lungs | Thalidomide + piroxicam |
| 24 | DSH | 9 | FN | 3.21 | Melanoma | 5 times a week | 20.0 | Macroscopic | LN and lungs | Meloxicam |
CYC = cyclophosphamide; DSH = domestic shorthair; DLH = domestic longhair; F = female; N = neutered; M = male; EOD = every other day; LN = lymph nodes